Equity Research interview preparation
Sell side and buy side. Every question is either traced to a named firm from a public candidate report, or tagged at desk level when we could not trace it. Answers lead with the point, then the mechanism, then the limitation.
100 questions, mapped to the firms that asked them
- Questions
- 100
- Traced to a firm
- 72
- Firms
- 45
- Updated
- September 2026
007Would you rather buy a low quality business at a great price, or a high quality business at an okay price?Coatue ManagementTechnology, Media and Telecom · New York · 2023
Say this
High quality at an okay price, and the reason is compounding. A great business reinvests at high returns, so time works for you. In a cheap bad business, time works against you and you need the re-rating to happen quickly.
Then walk it
- The mathematical case: if a business earns 25 percent on incremental capital and can reinvest, your return converges on that reinvestment rate over a long hold, almost regardless of a sensible entry multiple.
- In a low-return business, the opposite happens. Every year you hold it, the intrinsic value is eroding, so the return depends entirely on the gap closing fast. You are renting a re-rating, not owning a compounder.
- So the horizon determines the answer, and I would say that explicitly. For a five-year hold, quality wins. For a six-month event-driven trade with a catalyst, the cheap asset can be the better risk-reward.
- The honest counterargument: 'high quality' is often just a description of a stock that has already worked, and paying any price for quality is how people lost money in 2021. Quality at an okay price is fine; quality at any price is not.
- My answer would be: quality, with a valuation discipline, because the error that permanently destroys capital is owning a declining business, while the error of overpaying for a good one is usually recoverable with time.
Where candidates lose it
Giving a textbook Buffett answer with no acknowledgement of the horizon or the risk of overpaying for quality. The question is testing whether you have an actual philosophy you can defend, including its weakness.
Expect next
- What is your investment philosophy and what formed it?
- When does the cheap asset win?
- How do you avoid a value trap?
Reported by candidates at Coatue Management (Technology, Media and Telecom, New York, 2023). Source: Wall Street Oasis.
035Tell me about a time someone questioned your integrity.BNY MellonEquity Research · New York · 2022
Say this
Choose a case where the challenge was reasonable given what the other person could see, and where you resolved it by showing your work. The point is how you respond to being doubted, not that you were vindicated.
Then walk it
- Pick something real but bounded: a number in your analysis that someone thought was wrong, a result that looked too good, a process someone thought you had skipped.
- Explain why the doubt was reasonable from their position. Starting with 'they were being unfair' reads badly and misses the point of the question.
- Then the response: you showed the working, walked them through the source data, or invited them to check it. Transparency rather than argument.
- Then the outcome, and if you had made an error, say so. Admitting a mistake here is stronger than a clean vindication, because it shows how you behave when you are actually wrong.
- Then the lasting change: how you document or communicate differently now. In research, where your entire product is a claim, being auditable is the whole professional standard.
Where candidates lose it
Getting defensive in the retelling, or choosing an example so serious that it raises new questions. Regulated firms ask this to see whether you respond to scrutiny with openness or with resistance.
Expect next
- What if you had actually been wrong?
- Tell me about an ethical dilemma you faced.
- How do you make your work auditable?
Reported by candidates at BNY Mellon (Equity Research, New York, 2022). Source: Wall Street Oasis.
082How would you handle publishing a sell rating on a company your bank has a relationship with?Sell-side research
Say this
Publish it, and rely on the structures that exist for exactly this: research is separated from banking, the rating is based on documented analysis, and compliance reviews it. The answer is process, not courage.
Then walk it
- Start with the structural point: research and investment banking are separated by information barriers, and the analyst's rating is not subject to banking sign-off. That separation exists because of past abuses and is enforced by regulation.
- Then the professional standard: the rating must follow the analysis, and the analysis must be documented so it can be defended. If the work supports a sell, the rating is a sell.
- Then the practical handling: make sure the note is factually impeccable, put the reasoning in the open, and give the company the chance to correct factual errors, not conclusions.
- Acknowledge the real cost honestly, because pretending there is none is naive: you may lose management access, which degrades your product. That is a genuine professional cost and it is why the skew exists.
- Then the escalation path: if you were pressured, you raise it with compliance and supervisory analysts. Knowing there is a channel is the answer they want.
- And the credibility argument: an analyst who never publishes a sell has a rating scale worth nothing. The value of your buy recommendations depends on your willingness to say sell.
Where candidates lose it
Either an idealistic 'I would just publish it' with no awareness of the structures, or a suggestion that you would soften the view. Name the information barrier and compliance explicitly; this is partly a regulatory-awareness question.
Expect next
- What if a senior banker called you about it?
- Why do so few sell ratings get published?
- How do you maintain company access after a downgrade?
088How do you avoid confirmation bias in your research?Hedge fundsAsset management
Say this
Build the disconfirming case deliberately rather than waiting to encounter it. Write the bear case before you buy, define in advance what would falsify the thesis, and seek out the best argument against you.
Then walk it
- Pre-commit the falsifier. When you initiate, write down the specific observable outcome that would prove you wrong, with a date. Then you cannot rationalise it later.
- Write the opposing case yourself, properly, not a straw man. If you cannot write a persuasive bear case, you do not understand the stock well enough to own it.
- Actively read the other side: the short reports, the bearish sell-side note, the competitor's investor day. Seek out the smartest person who disagrees.
- Structure the review so it starts from the evidence rather than from your note. Re-underwriting the position from scratch once a year, ignoring what you previously wrote, is the most effective single habit.
- Use a team process: have someone else argue the other side, or present the bear case yourself to the portfolio manager. Making the disconfirming work someone's explicit job is how good funds handle it.
- And watch for the behavioural tell: noticing that you are discounting bad news because it is inconvenient. Catching that in yourself is most of the battle.
Where candidates lose it
Giving a generic 'I try to stay objective'. Everyone believes that; that is what makes the bias work. The answer needs specific mechanisms, pre-commitment and structured disconfirmation, not intentions.
Expect next
- What would falsify your current best idea?
- How do you handle it when a position moves against you?
- Who do you go to for the other side?
Firm tags come from public, anonymous candidate reports on Wall Street Oasis: strong signal, not sworn testimony. Firms are named as the places a question was reported, not as partners of Fin Maverick. Answers are written for this page to show how to think out loud; they are not scripts to recite.

